Chinese agriculture officials approved Zhejiang Hisun Pharmaceutical (SHA:600267) subsidiary Zhejiang Hisun Animal Health Products' two medications for dogs, according to a Friday filing with the Shanghai Stock Exchange.
Pimobendan chewable tablets treat congestive heart failure in dogs caused by valve insufficiency, as well as preclinical dilated cardiomyopathy in large dogs, and other heart problems, the filing said.
Caprofen injection ins used to relieve osteoarthritic inflammation in dogs, as well as operative pain for soft tissue and bone surgery in canines, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments